Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

Basit Öğe Kaydı
dc.authorscopusid12794831300
dc.authorscopusid13205593600
dc.authorscopusid7004438602
dc.authorscopusid8392501600
dc.authorscopusid55542843700
dc.authorscopusid14630767100
dc.authorscopusid6506739457
dc.contributor.authorKalyoncu, Umut
dc.contributor.authorPehlivan, Yavuz
dc.contributor.authorAkar, Servet
dc.contributor.authorKaşifoğlu, Timuçin
dc.contributor.authorKimyon, G.
dc.contributor.authorKaradağ, Ö.
dc.contributor.authorKiraz, Sedat
dc.contributor.authorMercan, Rıdvan
dc.date.accessioned2022-05-11T14:05:02Z
dc.date.available2022-05-11T14:05:02Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. © TÜBİTAK.
dc.description.sponsorshipThis study was funded by Hacettepe Rheumatology Society.
dc.identifier.doi10.3906/sag-2012-5
dc.identifier.endpage1623
dc.identifier.issn1300-0144
dc.identifier.issue4en_US
dc.identifier.pmid33611869
dc.identifier.scopus2-s2.0-85114289836
dc.identifier.scopusqualityQ3
dc.identifier.startpage1615
dc.identifier.urihttps://doi.org/10.3906/sag-2012-5
dc.identifier.urihttps://hdl.handle.net/20.500.11776/4875
dc.identifier.volume51
dc.identifier.wosWOS:000691544700002
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMercan, Rıdvan
dc.language.isoen
dc.publisherTurkiye Klinikleri
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBiologic DMARDs
dc.subjectCOVID-19
dc.subjectRheumatoid arthritis
dc.subjectSpondyloarthritis
dc.subjectabatacept
dc.subjectadalimumab
dc.subjectcertolizumab pegol
dc.subjectdisease modifying antirheumatic drug
dc.subjectetanercept
dc.subjectgolimumab
dc.subjecthydroxychloroquine
dc.subjectinfliximab
dc.subjectleflunomide
dc.subjectmethotrexate
dc.subjectrituximab
dc.subjectsalazosulfapyridine
dc.subjectsecukinumab
dc.subjecttocilizumab
dc.subjectantirheumatic agent
dc.subjectadult
dc.subjectaged
dc.subjectAnkylosing Spondylitis Disease Activity Score
dc.subjectArticle
dc.subjectBath ankylosing spondylitis disease activity index
dc.subjectBath ankylosing spondylitis functional index
dc.subjectcohort analysis
dc.subjectcoronavirus disease 2019
dc.subjectCrohn Disease Activity Index
dc.subjectDAS28
dc.subjectdisease activity
dc.subjectdrug withdrawal
dc.subjecterythrocyte sedimentation rate
dc.subjectfemale
dc.subjectHealth Assessment Questionnaire
dc.subjecthealth status
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectobservational study
dc.subjectpandemic
dc.subjectpolymerase chain reaction
dc.subjectprospective study
dc.subjectquestionnaire
dc.subjectremission
dc.subjectrheumatoid arthritis
dc.subjectSimplified Disease Activity Index
dc.subjectspondylarthritis
dc.subjectvisual analog scale
dc.subjectadolescent
dc.subjectmedication compliance
dc.subjectmiddle aged
dc.subjectpandemic
dc.subjectregister
dc.subjectrheumatoid arthritis
dc.subjectvery elderly
dc.subjectyoung adult
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntirheumatic Agents
dc.subjectArthritis, Rheumatoid
dc.subjectCohort Studies
dc.subjectCOVID-19
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMedication Adherence
dc.subjectMiddle Aged
dc.subjectPandemics
dc.subjectProspective Studies
dc.subjectRegistries
dc.subjectSARS-CoV-2
dc.subjectYoung Adult
dc.titlePreferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
dc.title.alternativePreferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the covid-19 pandemic
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4875.pdf
Boyut:
181.8 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu